Table 1 Characteristics of patients and treatments.
From: Automatic detection and multi-component segmentation of brain metastases in longitudinal MRI
Demographics | |
|---|---|
Gender | |
Females | 18 (36.7%) |
Males | 31 (63.3%) |
Age (years) | |
Average | 65.78 |
Median | 66 |
Standard deviation | 11.96 |
Diagnosis | |
Primary site of melanoma | |
Trunk | 15 (30.6%) |
Lower limb | 9 (18.4%) |
Head and neck | 7 (14.3%) |
Upper limb | 6 (12.2%) |
Mucosal | 2 (4.1%) |
Choroid | 1 (2%) |
Unknown | 9 (18.4%) |
Treatments | |
Technique of radiosurgery (number of treatments) [a] | |
CyberKnife | 48 |
Gamma Knife | 26 |
Systemic treatments, number (%) of patients receiving | |
Checkpoint inhibitors | |
Ipilimumab (anti-CTLA-4) | 27 (55.1%) |
Nivolumab (anti-PD1) | 21 (42.8%) |
Relatlimab (LAG-3 inhibitor) | 4 (8.2%) |
Oncolytic viral immunotherapy | |
Talimogene laherparepvec (T-VEC) | 2 (4.1%) |
BRaf- and MEK-selective inhibitors | 9 (18.4%) |
BRAF inhibitors | |
Vemurafenib | 14 (28.6%) |
Dabrafenib | 12 (24.5%) |
MEK inhibitors | |
Trametinib | 15 (30.6%) |
Cobimetinib | 3 (6.1%) |
Tyrosine kinase inhibitors | |
Sorafenib | 3 (6.1%) |
Lapatinib | 1 (2%) |
Pazopanib | 1 (2%) |
Chemotherapies | |
Temozolomide | 11 (22.4%) |
Dacarbazine | 9 (18.4%) |
Carboplatin-Taxol | 5 (10.2%) |
Nab-paclitaxel | 3 (6.1%) |
Fotemustine | 2 (4.1%) |
